{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:53:13Z","timestamp":1792443193537,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthroplasty"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The gold standard to decrease total joint arthroplasty (TJA) periprosthetic joint infection (PJI) is preoperative antibiotic prophylaxis. Despite substantial prevention efforts, rates of PJIs are increasing. While cefazolin is the drug of choice for preoperative prophylaxis, adjunctive vancomycin therapy has been used in methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) endemic areas. However, studies examining these combinations are lacking. Therefore, we sought to examine complications among vancomycin plus cefazolin and cefazolin-only recipients prior to primary TJA in a single institutional sample and specifically assessed: (1) microbiological aspects, including periprosthetic joint and surgical site infections, microbes cultured from the infection, and frequency of microbes cultured from nasal swab screening; (2) 30-day emergency department (ED) visits and re-admissions; as well as (3) associated risk factors for infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 2,907 patients (1,437 receiving both cefazolin and vancomycin and 1,470 given cefazolin only) who underwent primary TJA between 1 January 2014 and 31 May 2021 were identified. SSI and PJI as well as rates of cultured microbes rates were obtained through one year, those with prior nasal swab screening and 30-day re-admission were identified. Subsequently, multiple regression analyses were performed to investigate potential independent risk factors for PJIs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was no significant difference in the rates of SSI (<jats:italic>P<\/jats:italic>\u2009=\u20090.089) and PJI (<jats:italic>P<\/jats:italic>\u2009=\u20090.279) between the groups at one year after operation. Commonly identified organisms included <jats:italic>Staphylococcus<\/jats:italic> and <jats:italic>Streptococcus<\/jats:italic> species<jats:italic>.<\/jats:italic> The VC cohort did have a greater reduction of MRSA in the previously nasal swab-screened subset of patients. Multiple regression analyses demonstrated emergency as well as inpatient admissions as risk factors for PJI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Adjunctive vancomycin therapy offers increased protection against MRSA in previously screened individuals. However, those negative for MRSA screening do not require vancomycin and have similar protection to infection compared to recipients of cefazolin only in a high-powered single institution analysis in an MRSA endemic area.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42836-023-00222-2","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T13:01:51Z","timestamp":1709902911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Addition of vancomycin to cefazolin is often unnecessary for preoperative antibiotic prophylaxis during total joint arthroplasties"],"prefix":"10.1186","volume":"6","author":[{"given":"Sandeep S.","family":"Bains","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A.","family":"Dubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashesh","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald E.","family":"Delanois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"222_CR1","doi-asserted-by":"publisher","DOI":"10.1302\/2058-5241.6.210008","author":"T Karachalios","year":"2021","unstructured":"Karachalios T, Komnos GA. Management strategies for prosthetic joint infection: long-term infection control rates, overall survival rates, functional and quality of life outcomes. EFORT Open Rev. 2021. https:\/\/doi.org\/10.1302\/2058-5241.6.210008.","journal-title":"EFORT Open Rev"},{"key":"222_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2012.02.022","author":"SM Kurtz","year":"2012","unstructured":"Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the united states. J Arthroplasty. 2012. https:\/\/doi.org\/10.1016\/j.arth.2012.02.022.","journal-title":"J Arthroplasty"},{"key":"222_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1302\/2633-1462.31.BJO-2021-0051.R1","volume":"3","author":"DB Buchalter","year":"2022","unstructured":"Buchalter DB, Nduaguba A, Teo GM, et al. Cefazolin remains the linchpin for preventing acute periprosthetic joint infection following primary total knee arthroplasty. Bone Jt Open. 2022;3:35\u201341. https:\/\/doi.org\/10.1302\/2633-1462.31.BJO-2021-0051.R1.","journal-title":"Bone Jt Open"},{"key":"222_CR4","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1086\/519470","volume":"45 Suppl 3","author":"MH Kollef","year":"2007","unstructured":"Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis. 2007;45 Suppl 3:S191-5.","journal-title":"Clin Infect Dis"},{"key":"222_CR5","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1086\/518452","volume":"44","author":"S Deresinski","year":"2007","unstructured":"Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence. Clin Infect Dis. 2007;44:1543\u20138.","journal-title":"Clin Infect Dis"},{"key":"222_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2018.03.009","author":"JR Burger","year":"2018","unstructured":"Burger JR, Hansen BJ, Leary EV, et al. Dual-agent antibiotic prophylaxis using a single preoperative vancomycin dose effectively reduces prosthetic joint infection rates with minimal renal toxicity risk. J Arthroplasty. 2018. https:\/\/doi.org\/10.1016\/j.arth.2018.03.009.","journal-title":"J Arthroplasty"},{"key":"222_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2012.03.040","author":"EB Smith","year":"2012","unstructured":"Smith EB, Wynne R, Joshi A, et al. Is it time to include vancomycin for routine perioperative antibiotic prophylaxis in total joint arthroplasty patients? J Arthroplasty. 2012. https:\/\/doi.org\/10.1016\/j.arth.2012.03.040.","journal-title":"J Arthroplasty"},{"key":"222_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002340","author":"W Branch-Elliman","year":"2017","unstructured":"Branch-Elliman W, Ripollone JE, O\u2019Brien WJ, et al. Risk of surgical site infection, acute kidney injury, and Clostridium difficile infection following antibiotic prophylaxis with vancomycin plus a beta-lactam versus either drug alone: a national propensity-score-adjusted retrospective cohort study. PLoS Med. 2017. https:\/\/doi.org\/10.1371\/journal.pmed.1002340.","journal-title":"PLoS Med"},{"key":"222_CR9","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1007\/s11999-012-2255-1","volume":"470","author":"A Sewick","year":"2012","unstructured":"Sewick A, Makani A, Wu C, et al. Does dual antibiotic prophylaxis better prevent surgical site infections in total joint arthroplasty? Clin Orthop Relat Res. 2012;470:2702\u20137.","journal-title":"Clin Orthop Relat Res"},{"key":"222_CR10","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1695742","author":"JM Villa","year":"2020","unstructured":"Villa JM, Pannu TS, Riesgo AM, et al. Dual antibiotic prophylaxis in total knee arthroplasty: where do we stand? J Knee Surg. 2020. https:\/\/doi.org\/10.1055\/s-0039-1695742.","journal-title":"J Knee Surg"},{"key":"222_CR11","doi-asserted-by":"publisher","unstructured":"Cohen-Rosenblum A, Crutcher M, Gui J, et al. Dual antibiotic therapy with vancomycin and cefazolin for surgical prophylaxis in total knee arthroplasty. Reconstruct Rev. 2018. https:\/\/doi.org\/10.15438\/rr.8.2.212.","DOI":"10.15438\/rr.8.2.212"},{"key":"222_CR12","doi-asserted-by":"publisher","DOI":"10.2106\/jbjs.m.00663","author":"B Ponce","year":"2014","unstructured":"Ponce B, Raines BT, Reed RD, et al. Surgical site infection after arthroplasty: comparative effectiveness of prophylactic antibiotics. J Bone Joint Surg. 2014. https:\/\/doi.org\/10.2106\/jbjs.m.00663.","journal-title":"J Bone Joint Surg"},{"key":"222_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1128\/CMR.00081-09","volume":"23","author":"MZ David","year":"2010","unstructured":"David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23:616\u201387.","journal-title":"Clin Microbiol Rev"},{"key":"222_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1089\/sur.2010.083","volume":"12","author":"LH Rosenberger","year":"2011","unstructured":"Rosenberger LH, Politano AD, Sawyer RG. The surgical care improvement project and prevention of post-operative infection, including surgical site infection. Surg Infect. 2011;12:163\u20138.","journal-title":"Surg Infect"},{"key":"222_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2018.02.078","author":"J Parvizi","year":"2018","unstructured":"Parvizi J, Tan TL, Goswami K, et al. The 2018 definition of periprosthetic hip and knee infection: an evidence-based and validated criteria. J Arthroplasty. 2018. https:\/\/doi.org\/10.1016\/j.arth.2018.02.078.","journal-title":"J Arthroplasty"},{"key":"222_CR16","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198700342-00007","author":"DM Livermore","year":"1987","unstructured":"Livermore DM. Mechanisms of resistance to cephalosporin antibiotics. Drugs. 1987. https:\/\/doi.org\/10.2165\/00003495-198700342-00007.","journal-title":"Drugs"},{"key":"222_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3947\/ic.2013.45.2.117","volume":"45","author":"K Hiramatsu","year":"2013","unstructured":"Hiramatsu K, Ito T, Tsubakishita S, et al. Genomic basis for methicillin resistance in Staphylococcus aureus. Infect Chemother. 2013;45:117\u201336.","journal-title":"Infect Chemother"},{"key":"222_CR18","first-page":"269","volume":"90","author":"WA McGuinness","year":"2017","unstructured":"McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017;90:269\u201381.","journal-title":"Yale J Biol Med"},{"key":"222_CR19","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/pro.3819","volume":"29","author":"PJ Stogios","year":"2020","unstructured":"Stogios PJ, Savchenko A. Molecular mechanisms of vancomycin resistance. Protein Sci. 2020;29:654\u201369.","journal-title":"Protein Sci"},{"key":"222_CR20","doi-asserted-by":"publisher","DOI":"10.1590\/S1413-86702002000400007","author":"JLL Rocha","year":"2002","unstructured":"Rocha JLL, Kondo W, Baptista MIDK, et al. Uncommon vancomycin-induced side effects. Braz J Infect. 2002. https:\/\/doi.org\/10.1590\/S1413-86702002000400007.","journal-title":"Braz J Infect"},{"key":"222_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz974","author":"KA Mergenhagen","year":"2020","unstructured":"Mergenhagen KA, Starr KE, Wattengel BA, et al. Determining the utility of methicillin-resistant staphylococcus aureus nares screening in antimicrobial stewardship. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciz974.","journal-title":"Clin Infect Dis"},{"key":"222_CR22","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/phar.2188","volume":"38","author":"AL Carr","year":"2018","unstructured":"Carr AL, Daley MJ, Givens Merkel K, Rose DT. Clinical utility of methicillin-resistant staphylococcus aureus nasal screening for antimicrobial stewardship: a review of current literature. Pharmacotherapy. 2018;38:1216\u201328.","journal-title":"Pharmacotherapy"},{"key":"222_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13018-020-01601-0","volume":"15","author":"X Zhu","year":"2020","unstructured":"Zhu X, Sun X, Zeng Y, et al. Can nasal Staphylococcus aureus screening and decolonization prior to elective total joint arthroplasty reduce surgical site and prosthesis-related infections? A systematic review and meta-analysis. J Orthop Surg Res. 2020;15:60.","journal-title":"J Orthop Surg Res"},{"key":"222_CR24","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s11999-013-2875-0","volume":"471","author":"AF Chen","year":"2013","unstructured":"Chen AF, Wessel CB, Rao N. Staphylococcus aureus screening and decolonization in orthopaedic surgery and reduction of surgical site infections infection. Clin Orthop Relat Res. 2013;471:2383\u201399.","journal-title":"Clin Orthop Relat Res"},{"key":"222_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-005-0649-3","author":"B Sankar","year":"2005","unstructured":"Sankar B, Hopgood P, Bell KM. The role of MRSA screening in joint-replacement surgery. Int Orthop. 2005. https:\/\/doi.org\/10.1007\/s00264-005-0649-3.","journal-title":"Int Orthop"},{"key":"222_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.otsr.2013.03.030","author":"PY Levy","year":"2013","unstructured":"Levy PY, Ollivier M, Drancourt M, et al. Relation between nasal carriage of Staphylococcus aureus and surgical site infection in orthopedic surgery: the role of nasal contamination. A systematic literature review and meta-analysis. Orthop Traumatol Surg Res. 2013. https:\/\/doi.org\/10.1016\/j.otsr.2013.03.030.","journal-title":"Orthop Traumatol Surg Res"},{"key":"222_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-017-5302-0","author":"MM Kheir","year":"2017","unstructured":"Kheir MM, Tan TL, Azboy I, et al. Vancomycin prophylaxis for total joint arthroplasty: incorrectly dosed and has a higher rate of periprosthetic infection than cefazolin. Clin Orthop Relat Res. 2017. https:\/\/doi.org\/10.1007\/s11999-017-5302-0.","journal-title":"Clin Orthop Relat Res"},{"key":"222_CR28","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.2106\/JBJS.H.01219","volume":"91","author":"J Meehan","year":"2009","unstructured":"Meehan J, Jamali AA, Nguyen H. Prophylactic antibiotics in hip and knee arthroplasty. J Bone Joint Surg. 2009;91:2480\u201390.","journal-title":"J Bone Joint Surg"},{"key":"222_CR29","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/cid\/cis027","volume":"54","author":"T Crawford","year":"2012","unstructured":"Crawford T, Rodvold KA, Solomkin JS. Vancomycin for surgical prophylaxis? Clin Infect Dis. 2012;54:1479\u20139.","journal-title":"Clin Infect Dis"}],"container-title":["Arthroplasty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42836-023-00222-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42836-023-00222-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42836-023-00222-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T13:05:12Z","timestamp":1709903112000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthroplasty.biomedcentral.com\/articles\/10.1186\/s42836-023-00222-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["222"],"URL":"https:\/\/doi.org\/10.1186\/s42836-023-00222-2","relation":{},"ISSN":["2524-7948"],"issn-type":[{"value":"2524-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"assertion":[{"value":"28 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.E.D.: Research support from Biocomposites Inc., CyMedica Orthopedics, DePuy Synthes Product Inc., Flexion Therapeutics, Microport Orthopedics Inc., Orthofix Inc., PatientCentered Outcomes Research Institute (PCORI), Smith & Nephew, Stryker, Tissue Gene and United Orthopedic Corporation; J.N.: Research support from: Microport Orthopedics Inc., Stryker and United Orthopedic Corporation; The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}